海利尔药业集团股份有限公司 关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告

Core Points - The company has approved the first grant of restricted stock under the 2025 Restricted Stock Incentive Plan, with a total of 11.5 million shares to be granted to 618 recipients at a price of 7.28 yuan per share, effective on October 30, 2025 [2][6][23] Summary by Sections Grant Details - The first grant date for the restricted stock is set for October 30, 2025 [2] - A total of 11.5 million shares will be granted [2] - The grant price is established at 7.28 yuan per share [6] Decision Process - The decision-making process involved multiple meetings, including the board meeting on September 29, 2025, where the incentive plan was reviewed and approved [3][4] - The internal list of incentive recipients was publicly disclosed from October 9 to October 18, 2025, with no objections received [3] - The plan was approved by the shareholders at the first extraordinary general meeting on October 29, 2025 [4][5] Compliance and Conditions - The board confirmed that both the company and the recipients meet the necessary conditions for granting the restricted stock, as outlined in the relevant regulations [5][6] - The incentive plan includes performance assessment criteria that must be met for the release of the restricted stock [7][9] Financial Impact - The estimated total cost of the restricted stock incentive plan is projected to be 81.995 million yuan, with specific amortization details provided [19][20] - The actual financial impact will be determined based on the final audit report [20] Legal Opinions - Legal counsel has confirmed that all necessary approvals and authorizations for the stock grant have been obtained, and the conditions for granting the stock have been satisfied [21]